Ottawa – Health Canada has approved a new vaccine to protect two groups most severely affected by the respiratory syncytial virus (RSV): newborns, who would receive antibodies through maternal immunization, and Canadians over 60. Pfizer Canada’s bivalent vaccine, called Abrysvo, aims to prevent lower respiratory tract disease caused by the virus. It is the first RSV vaccine in Canada approved …